CANF
Can-Fite BioPharma Ltd.
There isn't enough reported data to score CANF yet.
LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
CANF Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
CANF's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
CANF PE Valuation
CANF has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
CANF Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong decline | |
| -- | |
| Limited | |
| High |
Analysts expect CANF's revenue to decline, with its earnings and profitability holding steady.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
CANF Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2023 | -$2.00 | +$2.00 |
| Q4 2022 | -$2.00 | +$4.00 |
| Q2 2022 | -$4.00 | -$2.00 |
| Q4 2021 | -$6.00 | +$2.00 |
| Q4 2020 | -$8.00 | +$14.00 |
| Q4 2019 | -$22.00 | -104% |
| Q4 2018 | $510.00 | -11% |
CANF is still losing money, but far less than before: $0.00 per share over the past year, against $22.00 at its worst in late 2019.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over CANF in the latest year-over-year earnings comparison.
CANF Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2025 | $203K | -43% |
| Q2 2025 | $202K | -36% |
| Q4 2024 | $358K | +2% |
| Q2 2024 | $316K | -19% |
| Q4 2023 | $351K | -12% |
| Q2 2023 | $392K | -4.2% |
| Q4 2022 | $401K | -12% |
| Q2 2022 | $409K | +2.8% |
CANF's revenue has slid since its 2018 peak: $203,000 last quarter, down 42% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2025 | -2489% | -1435 points |
| Q2 2025 | -2425% | -1278 points |
| Q4 2024 | -1127% | +283 points |
| Q2 2024 | -1296% | -210 points |
| Q4 2023 | -1054% | +603 points |
| Q2 2023 | -1147% | +186 points |
| Q4 2022 | -1410% | +260 points |
| Q2 2022 | -1086% | +931 points |
CANF's operating margin was −2489% last quarter, down 1435 points from the same quarter a year ago, near the bottom of its range since 2017.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over CANF in the latest year-over-year revenue comparison.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY's operating margin was 34% last quarter, down 6.6 points from the same quarter a year ago.
CANF Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q4 2025 | -$4.2M | -$596K |
| Q2 2025 | -$4.8M | -$713K |
| Q4 2024 | -$3.6M | -$207K |
| Q2 2024 | -$4M | +$1M |
| Q4 2023 | -$3.4M | +$1.3M |
| Q2 2023 | -$5M | +$1M |
| Q4 2022 | -$4.7M | +$1.7M |
| Q2 2022 | -$6.1M | -$2.6M |
CANF has burned cash in almost every quarter: −$17M over the past year, against −$19M the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY generated $19.7B in free cash flow over the past year, up 112% from the year before.
CANF Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +87% | +79.5M shares |
| 1 year | +4083% | +167M shares |
CANF has 171M diluted shares, up 4083% from a year ago.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over CANF on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
CANF Net Leverage
CANF's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
CANF Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 26.8 | Oversold |
| Stochastic | 2.7 | Oversold |
CANF's weekly RSI is 27 (oversold) and its Stochastic is 3 (oversold).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
CANF PE vs Healthcare Sector
CANF has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
CANF Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.81 | 18% below |
| 20 week MA | $2.59 | 42% below |
| 50 week MA | $3.33 | 55% below |
| 100 week MA | $12.2 | 88% below |
| 200 week MA | $30.8 | 95% below |
CANF is in a downtrend: it's below all five of its weekly moving averages, and 95% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over CANF on trend strength, trading above more of its moving averages.
CANF Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $690.0 | $370.0 | -46% |
| 2021 | $370.0 | $274.0 | -26% |
| 2022 | $274.0 | $128.0 | -53% |
| 2023 | $128.0 | $44.0 | -66% |
| 2024 | $44.0 | $31.6 | -28% |
| 2025 | $31.6 | $4.28 | -86% |
| 2026 YTD | $4.28 | $1.49 | -65% |
CANF has finished every year since 2020 lower, and it's down 65% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over CANF on returns for 2026, with the stronger performance.